Context Therapeutics
CNTX
19 hedge funds and large institutions have $9.44M invested in Context Therapeutics in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
22.24% more ownership
Funds ownership: 0% → 22.24% (+22%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$6.14M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.8M |
| 3 |
ACM
Altium Capital Management
New York
|
+$2.46M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.07M |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$872K |
Top Sellers
CNTX Hedge Fund Activity: Q4 2021 in Review
19 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q4 2021, worth a combined $9.44M.
Buyers outnumbered sellers: 19 funds opened new CNTX positions and 0 closed out — a net gain of 19 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $6.14M.
- 19 institutional investors held Context Therapeutics (CNTX) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $9.44M of Context Therapeutics stock for Q4 2021.
- 19 funds opened new Context Therapeutics positions in Q4 2021 and 0 closed out, a net change of +19 holders.
- The largest Context Therapeutics buyer in Q4 2021 was Sabby Management, an estimated $6.14M added.
Based on aggregated 13F filings for Q4 2021.